DOCSLIB.ORG

Bupropion ­ Wikipedia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bupropion ­ Wikipedia 13/01/2017 Bupropion ­ Wikipedia Bupropion From Wikipedia, the free encyclopedia Bupropion is a medication primarily used as an antidepressant Bupropion and smoking cessation aid.[6][7][8] It is marketed as Wellbutrin and Zyban among other trade names. It is one of the most frequently prescribed antidepressants in the United States and Canada,[9] although in many countries this is an off­label use.[10] It is an effective antidepressant on its own, but is also popular as an add­on medication in cases of incomplete response to first­ line SSRI antidepressants.[11] Bupropion is taken in tablet form and is available only by prescription in most countries.[9] The most important side effect is an increase in risk for epileptic seizures, which caused the drug to be withdrawn from the market for some time and then caused the recommended dosage to be reduced.[11] In comparison to many other antidepressants, it does not cause as much weight gain or sexual dysfunction.[11] Bupropion acts as an norepinephrine­dopamine reuptake inhibitor (NDRI). It is an atypical antidepressant, different from most commonly prescribed antidepressants such as selective 1 : 1 mixture (racemate) serotonin reuptake inhibitors (SSRIs).[10] Clinical data Pronunciation /bjuːˈproʊ.pi.ɒn/ Bupropion is known to affect several different biological bew­ᐟᐣᐝᐏ­pee­on targets.[11][12] It often is described as a norepinephrine­dopamine Trade names Wellbutrin, Elontril, Zyban reuptake inhibitor (NDRI), and is also a nicotinic antagonist.[12][13] However, bupropion does not appear to have AHFS/Drugs.com Monograph (https://www.drugs. significant dopaminergic actions in humans under normal com/monograph/bupropion­hydr clinical circumstances.[12][14] Chemically, bupropion belongs to ochloride.html) the class of aminoketones and is similar in structure to MedlinePlus a695033 (https://medlineplus.go stimulants such as cathinone and amfepramone, and to v/druginfo/meds/a695033.html) [11] phenethylamines in general. License data US FDA: Bupropion (htt p://www.accessdata.fda.g Bupropion was first made by Nariman Mehta and patented by Burroughs Wellcome in 1969, which later became part of what ov/scripts/cder/drugsatfd is now GlaxoSmithKline. It was first approved for medical use a/index.cfm?fuseaction=S in the United States in 1989. It was originally called by the earch.SearchAction&Sear generic name amfebutamone, before being renamed in 2000.[15] chTerm=Bupropion&Sear chType=BasicSearch) Pregnancy AU: B2 category Contents US: C (Risk not ruled out) Dependence none to very low 1 Medical uses liability 1.1 Depression Addiction none to very low 1.2 Smoking cessation liability 1.3 Attention deficit hyperactivity disorder Routes of Medical: oral https://en.wikipedia.o1rg.4/wikSi/Beuxpuroaplio dnysfunction 1/16 13/01/2017 Bupropion ­ Wikipedia 1.4 Sexual dysfunction administration Recreational: insufflation, 1.5 Obesity intravenous 1.6 Other uses 2 Contraindications ATC code N06AX12 (WHO (http://www.w 3 Side effects hocc.no/atc_ddd_index/?code=N 3.1 Psychiatric 06AX12)) 4 Overdose Legal status 5 Interactions 6 Pharmacology Legal status AU: S4 (Prescription 6.1 Pharmacodynamics only) 6.1.1 Dopaminergic activity CA: ℞­only 6.1.2 Antinicotinic and other activities UK: POM (Prescription 6.2 Pharmacokinetics 7 Chemistry only) 7.1 Synthesis US: ℞­only 8 History Pharmacokinetic data 8.1 Issue with generic bioequivalence 9 Society and culture Protein binding 84% (bupropion), 77% 9.1 Names (hydroxybupropion metabolite), 9.2 Recreational use 42% (threohydrobupropion 10 References metabolite)[1] 11 External links Metabolism Hepatic (mostly CYP2B6­ mediated hydroxylation, but Medical uses with some contributions from CYP1A2, CYP2A6, CYP2C9, CYP3A4, CYP2E1 and Depression CYP2C19)[1][2][3][4] Bupropion is one of the most widely prescribed antidepressants, Biological half­ 12–30 hours[3][5] and the available evidence indicates that it is effective in clinical life depression[16] — as effective as several other widely prescribed Excretion Renal (87%; 0.5% unchanged), drugs, including fluoxetine (Prozac) and paroxetine (Paxil),[17] Faecal (10%)[1][2][3] although trends favoring the efficacy of escitalopram (Lexapro), Identifiers sertraline (Zoloft) and venlafaxine (Effexor) over bupropion IUPAC name have been observed.[17] Mirtazapine (Remeron), on the other Synonyms 3­Chloro­N­tert­butyl­β­keto­α­ hand is significantly more effective than bupropion.[17] methylphenethylamine; Bupropion has several features that distinguish it from other antidepressants: for instance, unlike the majority of 3­Chloro­N­tert­butylcathinone; bupropion hydrochloride; antidepressants, it does not usually cause sexual dysfunction.[18] Bupropion treatment also is not associated with the sleepiness or amfebutamone weight gain that may be produced by other antidepressants.[19] CAS Number 34911­55­2 (http://www.commo nchemistry.org/ChemicalDetail.a In depressed people who experience symptoms of sleepiness and spx?ref=34911­55­2) fatigue, bupropion has been found to be more effective than selective serotonin reuptake inhibitors (SSRIs) in alleviating PubChem (CID) 444 (https://pubchem.ncbi.nlm.n ih.gov/summary/summary.cgi?ci these symptoms.[20] There appears to be a modest advantage for the SSRIs over bupropion in the treatment of anxious d=444) depression.[21] IUPHAR/BPS 7135 (http://www.guidetopharm acology.org/GRAC/LigandDispla yForward?ligandId=7135) https://en.wikipedia.org/wiki/Bupropion 2/16 13/01/2017 Bupropion ­ Wikipedia According to surveys, the addition to a prescribed SSRI is a DrugBank DB01156 (https://www.drugban common strategy when people do not respond to the SSRI, even k.ca/drugs/DB01156) [22] though this is not an officially approved indication. The ChemSpider 431 (http://www.chemspider.co addition of bupropion to an SSRI (most commonly fluoxetine or sertraline) may result in an improvement in some people who m/Chemical­Structure.431.html) have an incomplete response to the first­line antidepressant.[22] UNII 01ZG3TPX31 (http://fdasis.nlm. Bupropion was approved by the U.S. Food and Drug nih.gov/srs/srsdirect.jsp?regno=0 Administration (FDA), in 2006, for the prevention of seasonal 1ZG3TPX31) affective disorder.[23] In some countries (including Australia, KEGG New Zealand and the UK) this is an off­label use.[24][25] D07591 (http://www.kegg.jp/ent ry/D07591) Smoking cessation ChEBI CHEBI:3219 (https://www.ebi.a c.uk/chebi/searchId.do?chebiId= The next most common use is as an aid for smoking CHEBI:3219) cessation.[26][27] Bupropion reduces the severity of nicotine ChEMBL CHEMBL894 (https://www.ebi. cravings and withdrawal symptoms.[28] Bupropion is helpful for ac.uk/chembldb/index.php/comp smoking cessation in smokers with no history of depression; thus, the effectiveness of bupropion is not due to its ound/inspect/CHEMBL894) antidepressant effect. A typical bupropion treatment course lasts Chemical and physical data up to twelve weeks, with the people halting the use of tobacco Formula C H ClNO about ten days into the course. Bupropion approximately 13 18 doubles the chance of quitting smoking successfully.[28] The Molar mass 239.74 g/mol effectiveness of bupropion is comparable to nicotine 3D model (Jmol) Interactive image (http://chemap replacement therapy, but less effective than varenicline.[28] ps.stolaf.edu/jmol/jmol.php?mod el=O%3DC%28C%28C%29N In Australia and the UK smoking cessation is the only licensed C%28C%29%28C%29C%29C [24][25] use of bupropion. 1%3DCC%3DCC%28Cl%29%3 DC1) Attention deficit hyperactivity disorder SMILES Bupropion has been used as a treatment for attention deficit InChI [29] hyperactivity disorder (ADHD) since at least 2004, with (what is this?) (verify) reports of positive results in both minors and adults.[30] In a double­blind study of children, while aggression and hyperactivity as rated by the children's teachers were significantly improved in comparison to placebo, parents and clinicians could not distinguish between the effects of bupropion and placebo.[30] The 2007 guideline on the ADHD treatment from American Academy of Child and Adolescent Psychiatry notes that the evidence for bupropion is "far weaker" than for the FDA­approved treatments. Its effect may also be "considerably less than of the approved agents ... Thus it may be prudent for the clinician to recommend a trial of behavior therapy at this point, before moving to these second­line agents."[31] Similarly, the Texas Department of State Health Services guideline recommends considering bupropion or a tricyclic antidepressant as a fourth­line treatment after trying two different stimulants and atomoxetine.[32] Wellbutrin XL Sexual dysfunction https://en.wikipedia.org/wiki/Bupropion 3/16 13/01/2017 Bupropion ­ Wikipedia Bupropion is one of few antidepressants that do not cause sexual dysfunction.[33] A range of studies demonstrate that bupropion not only produces fewer sexual side effects than other antidepressants, but can actually help to alleviate sexual dysfunction.[34] According to a survey of psychiatrists, it is the drug of choice for the treatment of SSRI­induced sexual dysfunction, although this is not an indication approved by the U.S. Food and Drug Administration. There have also been a few studies suggesting that bupropion can improve sexual function in women who are not depressed, if they have hypoactive sexual desire disorder (HSDD).[35] Obesity Bupropion, when used for treating obesity over a period of 6 to 12 months, may result in weight loss of 2.7 kg over placebo.[36] This is not much different
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • DART-MS/MS Screening for the Determination of 1,3- Dimethylamylamine and Undeclared Stimulants in Seized Dietary Supplements from Brazil
    Forensic Chemistry 8 (2018) 134–145 Contents lists available at ScienceDirect Forensic Chemistry journal homepage: www.elsevier.com/locate/forc DART-MS/MS screening for the determination of 1,3- dimethylamylamine and undeclared stimulants in seized dietary supplements from Brazil Maíra Kerpel dos Santos a, Emily Gleco b, J. Tyler Davidson b, Glen P. Jackson b, Renata Pereira Limberger a, ⇑ Luis E. Arroyo b, a Graduate Program of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Brazil b Department of Forensic & Investigative Science, West Virginia University, USA article info abstract Article history: 1,3-dimethylamylamine (DMAA) is an alkylamine with stimulating properties that has been used pre- Received 15 December 2017 dominantly as an additive in dietary supplements. DMAA is mostly consumed by professional athletes, Received in revised form 14 March 2018 and several doping cases reported since 2008 led to its prohibition by the World Anti-Doping Agency Accepted 18 March 2018 (WADA) in 2010. Adverse effects have indicated DMAA toxicity, and there is few data regarding its safety, Available online 22 March 2018 so it was banned by regulatory agencies from Brazil and the United States. Ambient ionization methods such as Direct Analysis in Real Time Tandem Mass Spectrometry (DART-MS/MS) are an alternative for Keywords: dietary supplements analysis, because they enable the analysis of samples at atmospheric pressure in 1,3-dimethylamylamine a very short time and with only minimal sample preparation. Therefore, the aim of this work was to DART-MS/MS Dietary supplements develop a methodology by DART-MS/MS to detect the presence of DMAA, ephedrine, synephrine, caffeine, Stimulants sibutramine, and methylphenidate in 108 dietary supplements seized by the Brazilian Federal Police Adulterants (BFP).
    [Show full text]
  • Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
    ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com.
    [Show full text]
  • 624.Full.Pdf
    1521-009X/44/5/624–633$25.00 http://dx.doi.org/10.1124/dmd.115.068932 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:624–633, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Development of a Rat Plasma and Brain Extracellular Fluid Pharmacokinetic Model for Bupropion and Hydroxybupropion Based on Microdialysis Sampling, and Application to Predict Human Brain Concentrations Thomas I.F.H. Cremers, Gunnar Flik, Joost H.A. Folgering, Hans Rollema, and Robert E. Stratford, Jr. Brains On-Line BV, Groningen, The Netherlands (T.I.F.H.C., G.F. J.H.A.F.); Rollema Biomedical Consulting, Mystic, Connecticut (H.R.); and Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania (R.E.S.) Received December 11, 2015; accepted February 24, 2016 Downloaded from ABSTRACT Administration of bupropion [(6)-2-(tert-butylamino)-1-(3-chlorophenyl) concentration ratio at early time points was observed with propan-1-one] and its preformed active metabolite, hydroxybupropion bupropion; this was modeled as a time-dependent uptake clear- [(6)-1-(3-chlorophenyl)-2-[(1-hydroxy-2-methyl-2-propanyl)amino]- ance of the drug across the blood–brain barrier. Translation of the 1-propanone], to rats with measurement of unbound concentrations model was used to predict bupropion and hydroxybupropion dmd.aspetjournals.org by quantitative microdialysis sampling of plasma and brain extra- exposure in human brain extracellular fluid after twice-daily cellular fluid was used to develop a compartmental pharmacoki- administration of 150 mg bupropion. Predicted concentrations netics model to describe the blood–brain barrier transport of both indicate that preferential inhibition of the dopamine and norepi- substances.
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture Of
    40 INCB REPORT ON PRECURSORS 2019 • 2,5-Dimethoxybenzaldehyde, a precursor for 2,5-dimethoxyamphetamine (DMA), brolamfetamine IV. Article 13 of the (DOB) and the 2C-series of controlled psychotropic substances, as well as for new psychoactive substances, 1988 Convention as reported by the Netherlands (5 kg) and Belgium (1 kg). a complementary tool in addressing • 4-Methoxy-P-2-P, a precursor of para-methoxy- alpha-methylphenethylamine (PMA) and para- illicit drug methoxymethylamphetamine (PMMA), reported by Spain (52 kg). manufacture 226. Through PICS, incidents involving 2-bromo- 4’-chloropropiophenone, a precursor of various 4-chloro- 229. The clandestine manufacture of narcotic drugs and substituted cathinone derivatives, such as 4-CMC psychotropic substances, new psychoactive substances and (clephedrone), were communicated. Luxembourg seized precursors is not possible without the input of chemicals, 500 kg of the substance in August 2018. The consignment materials and equipment. While the control of chemicals was confiscated because both the supplier and the con- has long been a focus of the authorities worldwide, pursu- signee were already known in connection with shipments ant to the provisions in article 12 of the 1988 Convention, of other precursors of new psychoactive substances. It much less attention has been given to equipment and originated in India, transited Qatar, Luxembourg and materials and article 13 of that Convention, which pro- Germany and was destined for a consignee in Poland. A vides a basis for international action and cooperation in consignment of 300 kg of the substance was confiscated by such control efforts (see box 5). customs authorities in Germany in December 2018.
    [Show full text]
  • FROM the LITERATURE PET in Assessment of Abuse Potential
    NEWSLINE FROM THE LITERATURE Each month the editor of Newsline drug radafaxine ([2S,3S])-2-[3-chlo- in the putamen. The authors con- selects articles on diagnostic, thera- rophenyl]-3,5,5,-trimethyl-2-mor- cluded that these and other data “sug- peutic, research, and practice issues pholinol hydrochloride). Radafaxine gest that the neurodegenerative from a range of international publica- is a potent metabolite of bupropion process in PD follows a negative ex- tions. Most selections come from out- that is being evaluated both as a treat- ponential course and slows down side the standard canon of nuclear ment for depression and for possible with increasing symptom duration, medicine and radiology journals. Note use in treatment of obesity. The study contradicting the long-latency hypo- that although we have divided the ar- included 8 healthy men who under- thesis of PD.” ticles into diagnostic and therapeutic went 11C-cocaine PET imaging at 1, Archives of Neurology categories, these lines are increasingly 4, 8, and 24 hours after radafaxine blurred as nuclear medicine capabili- administration. The authors found ties rapidly expand. Many diagnostic that DAT blockade by radafaxine PET and rCBF in Cocaine capabilities are now enlisted in direct was slow, reaching 11% at 1 hour Use Disorder support of and, often, in real-time con- and a peak blockade of 22% at 4 In an article e-published ahead of junction with, therapies. These briefs hours. The maximum blockade in print in the March 9 issue of the are offered as a monthly window on the any single subject was 33%.
    [Show full text]
  • Sibutramine Hydrochloride Monohydrate) Capsule CS-IV
    MERIDIA - sibutramine hydrochloride capsule ---------- MERIDIA® (sibutramine hydrochloride monohydrate) Capsule CS-IV DESCRIPTION MERIDIA® (sibutramine hydrochloride monohydrate) is an orally administered agent for the treatment of obesity. Chemically, the active ingredient is a racemic mixture of the (+) and (-) enantiomers of cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate, and has an empirical formula of C17H29Cl2NO. Its molecular weight is 334.33. The structural formula is shown below: Sibutramine hydrochloride monohydrate is a white to cream crystalline powder with a solubility of 2.9 mg/mL in pH 5.2 water. Its octanol: water partition coefficient is 30.9 at pH 5.0. Each MERIDIA capsule contains 5 mg, 10 mg, and 15 mg of sibutramine hydrochloride monohydrate. It also contains as inactive ingredients: lactose monohydrate, NF; microcrystalline cellulose, NF; colloidal silicon dioxide, NF; and magnesium stearate, NF in a hard-gelatin capsule [which contains titanium dioxide, USP; gelatin; FD&C Blue No. 2 (5- and 10-mg capsules only); D&C Yellow No. 10 (5- and 15-mg capsules only), and other inactive ingredients]. CLINICAL PHARMACOLOGY Mode of Action Sibutramine produces its therapeutic effects by norepinephrine, serotonin and dopamine reuptake inhibition. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. Pharmacodynamics Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin (5- hydroxytryptamine, 5-HT) and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Short-Term Difference in Mood with Sibutramine Versus Placebo in Obese Patients with and Without Depression
    RESEARCH ARTICLE Short-term difference in mood with sibutramine versus placebo in obese patients with and without depression Kristina Elfhag† & Background: Sibutramine is an anti-obesity satiety-enhancing drug which elicits its effect Stephan Rössner by inhibiting the reuptake of serotonin and noradrenalin. Objective: The aim of †Author for correspondence this study was to test the short-term effect on mood with sibutramine versus placebo in Karolinska University Hospital, Obesity Unit, M73, obese patients with and without depressive features. Materials & methods: The SE-141 86 Stockholm, participants consisted of 36 obese patients with a mean body mass index of 39 kg/m2. Sweden Depressive features were measured with the Comprehensive Psychopathological Rating Tel.: +46 858 582 478 [email protected] Scale (CPRS). Sibutramine (15 mg) and placebo were administered daily in a cross-over design over 14-day periods. At baseline, 19 (53%) patients demonstrated depressive features. Results: A significant short-term difference, implying lower mood with sibutramine versus placebo, was observed for depressed patients, in particular, in the CPRS subscale for anxiety. This result persisted as statistically significant also when removing an item on increased sleeping difficulties in the CPRS anxiety scale. Sleeping difficulties, which are common side effects of anti-obesity drugs, were also greater with sibutramine in depressed patients. No differences were found in the nondepressed population. Conclusion: Patients with depressive features can be more susceptible to experiencing a relatively higher initial discomfort with sibutramine compared with placebo at onset of treatment. Sibutramine is an anti-obesity drug which pri- improvements in sibutramine treatment have marily enhances satiety through a process of been reported in an additional study of obese serotonin and noradrenalin reuptake inhibition binge eating patents and in a general clinical [1].
    [Show full text]
  • Phenylmorpholines and Analogues Thereof Phenylmorpholine Und Analoge Davon Phenylmorpholines Et Analogues De Celles-Ci
    (19) TZZ __T (11) EP 2 571 858 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 265/30 (2006.01) A61K 31/5375 (2006.01) 20.06.2018 Bulletin 2018/25 A61P 25/24 (2006.01) A61P 25/16 (2006.01) A61P 25/18 (2006.01) (21) Application number: 11723158.9 (86) International application number: (22) Date of filing: 20.05.2011 PCT/US2011/037361 (87) International publication number: WO 2011/146850 (24.11.2011 Gazette 2011/47) (54) PHENYLMORPHOLINES AND ANALOGUES THEREOF PHENYLMORPHOLINE UND ANALOGE DAVON PHENYLMORPHOLINES ET ANALOGUES DE CELLES-CI (84) Designated Contracting States: • DECKER, Ann Marie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Durham, North Carolina 27713 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoeger, Stellrecht & Partner Patentanwälte mbB (30) Priority: 21.05.2010 US 347259 P Uhlandstrasse 14c 70182 Stuttgart (DE) (43) Date of publication of application: 27.03.2013 Bulletin 2013/13 (56) References cited: WO-A1-2004/052372 WO-A1-2008/026046 (73) Proprietors: WO-A1-2008/087512 DE-B- 1 135 464 • Research Triangle Institute FR-A- 1 397 563 GB-A- 883 220 Research Triangle Park, North Carolina 27709 GB-A- 899 386 US-A1- 2005 267 096 (US) • United States of America, as represented by • R.A. GLENNON ET AL.: "Beta-Oxygenated The Secretary, Department of Health and Human Analogues of the 5-HT2A Serotonin Receptor Services Agonist Bethesda, Maryland 20892-7660 (US) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopro pane", JOURNAL OF MEDICINAL CHEMISTRY, (72) Inventors: vol.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]